pegenzileukin

Pegenzileukin is a pegylated recombinant, engineered variant of interleukin‑2 (IL‑2) designed to selectively stimulate immune effector cells. It is created using site-specific pegylation at a novel amino acid in the IL‑2 gene, which blocks binding to the IL‑2 receptor alpha chain (CD25), thereby reducing activation of regulatory T cells and minimizing side effects such as vascular leak syndrome. This modification extends its half-life and enhances accumulation at tumor sites. Pegenzileukin primarily activates CD8+ T cells and natural killer (NK) cells, promoting anti-tumor immunity with improved tolerability compared to native IL‑2. The drug is being developed for various cancers including B-cell lymphoma, gastrointestinal cancer, Hodgkin's disease, malignant melanoma, mesothelioma, non-small cell lung cancer, squamous cell cancer, solid tumors, and multiple myeloma[1][3][4][5][8].

Other names

Non alpha IL-2 - SanofiNon alpha synthorin of IL-2 - Sanofi